ArticleJournal of cellular and molecular medicine2009
Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population.
Article in Journal of cellular and molecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Geometry of Gene Expression Space of Wilms' Tumors From Human Patients.Neoplasia (New York, N.Y.) · 2018Pooled it
- Gene Expression Analysis of (Paired) Primary and Relapsed Wilms Tumor Samples to Unravel the Underlying Factors Driving Tumor Recurrence.Cancer medicine · 2025Article
- A novel Frizzled 7 antibody disrupts the Wnt pathway and inhibits Wilms tumor growth.Frontiers in bioengineering and biotechnology · 2025Article
- Hallmark discoveries in the biology of Wilms tumour.Nature reviews. Urology · 2024Review
- Molecular subtyping and characterization of clear cell renal cell carcinoma by tumor differentiation trajectories.iScience · 2023Article
- Altered binding affinity of SIX1-Q177R correlates with enhanced WNT5A and WNT pathway effector expression in Wilms tumor.Disease models & mechanisms · 2023Article
- Single-Cell Transcriptional Landscape Reveals the Regulatory Network and Its Heterogeneity of Renal Mitochondrial Damages in Diabetic Kidney Disease.International journal of molecular sciences · 2023Article
- Characterization of alternative mRNA splicing in cultured cell populations representing progressive stages of human fetal kidney development.Scientific reports · 2022Article
- Wilms' Tumor Primary Cells Display Potent Immunoregulatory Properties on NK Cells and Macrophages.Cancers · 2021Article
- Human kidney clonal proliferation disclose lineage-restricted precursor characteristics.Scientific reports · 2020Article
- Isolation and characterisation of nasoseptal cartilage stem/progenitor cells and their role in the chondrogenic niche.Stem cell research & therapy · 2020Article
- Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor.Nature communications · 2019Article
- NCAM1/FGF module serves as a putative pleuropulmonary blastoma therapeutic target.Oncogenesis · 2019Article
- CD90/Thy-1, a Cancer-Associated Cell Surface Signaling Molecule.Frontiers in cell and developmental biology · 2019Review
- Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.World journal of pediatrics : WJP · 2018Article
- In Vivo Expansion of Cancer Stemness Affords Novel Cancer Stem Cell Targets: Malignant Rhabdoid Tumor as an Example.Stem cell reports · 2018Article
- Biomarker discovery for renal cancer stem cells.The journal of pathology. Clinical research · 2018Review
- Identification of new genes associated to senescent and tumorigenic phenotypes in mesenchymal stem cells.Scientific reports · 2017Article
- Article
- Evidence of In Vitro Preservation of Human Nephrogenesis at the Single-Cell Level.Stem cell reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During development, renal stem cells reside in the nephrogenic blastema. Wilms' tumour (WT), a common childhood malignancy, is suggested to arise from the nephrogenic blastema that undergoes partial differentiation and as such is an attractive model to study renal stem cells leading to cancer initiation and maintenance. Previously we have made use of blastema-enriched WT stem-like xenografts propagated in vivo to define a 'WT-stem' signature set, which includes cell surface markers convenient for cell isolation (frizzled homolog 2 [Drosophila] - FZD2, FZD7, G-protein coupled receptor 39, activin receptor type 2B, neural cell adhesion molecule - NCAM). We show by fluorescenceactivated cell sorting analysis of sphere-forming heterogeneous primary WT cultures that most of these markers and other stem cell surface antigens (haematopoietic, CD133, CD34, c-Kit; mesenchymal, CD105, CD90, CD44; cancer, CD133, MDR1; hESC, CD24 and putative renal, cadherin 11), are expressed in WT cell sub-populations in varying levels. Of all markers, NCAM, CD133 and FZD7 were constantly detected in low-to-moderate portions likely to contain the stem cell fraction. Sorting according to FZD7 resulted in extensive cell death, while sorted NCAM and CD133 cell fractions were subjected to clonogenicity assays and quantitative RT-PCR analysis, exclusively demonstrating the NCAM fraction as highly clonogenic, overexpressing the WT 'stemness' genes and topoisomerase2A (TOP2A), a bad prognostic marker for WT. Moreover, treatment of WT cells with the topoisomerase inhibitors, Etoposide and Irinotecan resulted in down-regulation of TOP2A along with NCAM and WT1. Thus, we suggest NCAM as a marker for the WT progenitor cell population. These findings provide novel insights into the cellular hierarchy of WT, having possible implications for future therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.